



83 1540

#33646

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
(Under 37 CFR 1.97(b) or 1.97(c))

Re Application:

Milbrandt, et al

Serial No.	Filing Date	Examiner	Group Art Unit
09/473,551	12/28/1999	Olga N. Chernyshev	1646

Docket No.

56029/9879

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of \_\_\_\_\_ is attached.

The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 20-0823 as described below. A duplicate copy of this sheet is enclosed.

Charge the amount of \_\_\_\_\_

Credit any overpayment.

Charge any additional fee required.

Certificate of Transmission by Facsimile\*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax No. \_\_\_\_\_) on \_\_\_\_\_

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on 11/26/02 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Daniel S. Kasten

Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

Signature

Daniel S. Kasten, Reg. #45363  
Thompson Coburn LLP  
One US Bank Plaza  
St. Louis, Missouri 63101  
314-552-6305  
314-552-7305 FAX

Dated: 11/26/02 RECEIVED

DEC 04 2002

TECH CENTER 1600/2900

CC:



STATEMENT UNDER 37 CFR 1.97(e) ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT

Docket No.  
56029-9879

In Re Application Of:  
MMBRANDT, et al

Serial No. 09/473,551	Filing Date 12/28/1999	Examiner Olga N. Chernyshev	Group Art Unit 1646
--------------------------	---------------------------	--------------------------------	------------------------

Invention:  
GFR (alpha)1-RET SPECIFIC AGONISTS AND METHODS THEREFOR

RECEIVED  
FEB 12 2003  
TECH CENTER 1600/2900

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

This is a statement under the provisions of 37 CFR 1.97(e) in the above-identified application.

Check applicable statement herebelow:

RECEIVED

DEC 04 2002

TECH CENTER 1600/2900

Statement Under 37 CFR 1.97(e)(1)

Each item of information contained in the accompanying Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

Statement Under 37 CFR 1.97(e)(2)

No item of information contained in the accompanying Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned person, after making reasonable inquiry, no item of information contained in the accompanying Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Daniel S. Kasten  
Signature

Dated:

Certificate of Mailing by First Class Mail

I certify that this document is being deposited on  
11/26/02 with the U.S. Postal Service as first  
class mail under 37 C.F.R. 1.8 and addressed to the  
Assistant Commissioner for Patents, Washington, D.C.  
20231.

Daniel S. Kasten  
Signature of Person Mailing Correspondence

Daniel S. Kasten

Typed or Printed Name of Person Mailing Correspondence

CC:



**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
56029/9879

In Re Application Of:  
MILLER, et al

Serial No.	Filing Date	Examiner	Group Art Unit
09/473,551	12/28/1999	Olga N. Chernyshev	1646

Title:

GFR (alpha)1-RET SPECIFIC AGONISTS AND METHODS THEREFOR

Address to:  
Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED  
FEB 12 2003  
TECH CENTER 1600/2900

**37 CFR 1.97(b)**

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

RECEIVED

DEC 04 2002

TECH CENTER 1600/2900